18-hydroxy-5,8,11,14-eicosatetraenoic acid profile

## 18-Hydroxy-5,8,11,14-eicosatetraenoic acid (18-HETE)

18-HETE is a **hydroxy-eicosatetraenoic acid (HETE)**, a type of **eicosanoid**. It's a bioactive lipid molecule derived from the **arachidonic acid** (AA) metabolism through the action of **cytochrome P450 (CYP) enzymes**, specifically CYP4A and CYP4F.

**Why is it important for research?**

18-HETE has been linked to a wide array of biological processes, including:

* **Inflammation:** It can promote inflammation by activating immune cells and producing inflammatory mediators.
* **Vascular function:** It can affect blood pressure regulation and vascular tone, potentially contributing to cardiovascular diseases.
* **Cancer:** Some studies suggest that 18-HETE may be involved in tumor growth and progression.
* **Neurological function:** It can impact neuronal activity and has been implicated in neurodegenerative diseases.
* **Metabolic disorders:** It may play a role in insulin resistance and obesity.

**Research implications:**

1. **Therapeutic targets:** Understanding the role of 18-HETE in these processes opens avenues for developing new drugs targeting its synthesis or signaling pathways to treat various diseases.
2. **Biomarkers:** 18-HETE levels can be used as potential biomarkers for monitoring inflammatory conditions, cardiovascular risk, and other disease states.
3. **Drug interactions:** Understanding how 18-HETE interacts with existing medications is crucial for ensuring drug safety and efficacy.
4. **Personalized medicine:** Individual differences in 18-HETE production and response could contribute to personalized medicine strategies.

**Current research:**

Ongoing research is focused on:

* Elucidating the exact mechanisms by which 18-HETE exerts its effects.
* Identifying specific targets for 18-HETE signaling.
* Developing novel inhibitors of 18-HETE biosynthesis.
* Exploring the potential of 18-HETE as a therapeutic agent or diagnostic marker.

**Overall, 18-HETE is an intriguing molecule with multifaceted biological roles, making it a crucial subject of ongoing research with significant implications for human health.**

18-hydroxy-5,8,11,14-eicosatetraenoic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6449793
MeSH ID	M0170390

Synonym
21914-83-0
5,8,11,14-eicosatetraenoic acid, 18-hydroxy-
18-hydroxy-5,8,11,14-eicosatetraenoic acid
18-hydroxyeicosatetraenoic acid
(5e,8e,11e,14e)-18-hydroxyicosa-5,8,11,14-tetraenoic acid

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (6.67)	18.7374
1990's	4 (26.67)	18.2507
2000's	2 (13.33)	29.6817
2010's	6 (40.00)	24.3611
2020's	2 (13.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (26.67%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (73.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
acetone methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).	1.98	1	0	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
glycine [no description available]	1.97	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
14,15-epoxy-5,8,11-eicosatrienoic acid 14,15-epoxy-5,8,11-eicosatrienoic acid: RN given refers to cpd without isomeric designation	1.99	1	0	long-chain fatty acid
tetraethylammonium Tetraethylammonium: A potassium-selective ion channel blocker. (From J Gen Phys 1994;104(1):173-90)	2.02	1	0	quaternary ammonium ion
phenylephrine Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.	2.02	1	0	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
ddms DDMS: a water soluble and highly specific inhibitor of cytochrome P-450 omega-hydroxylase	2.02	1	0	chlorophenylethane; monochlorobenzenes
n-(3,5-dinitrobenzoyl)phenylglycine N-(3,5-dinitrobenzoyl)phenylglycine: RN given for (R)-isomer	1.97	1	0
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	3.1	5	0	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
eicosapentaenoic acid icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.. all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.	5.39	4	3	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical
nadp [no description available]	1.99	1	0
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	2	1	0	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
8,11,14-eicosatrienoic acid 8,11,14-Eicosatrienoic Acid: A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.. all-cis-icosa-8,11,14-trienoic acid : An icosatrienoic acid having three cis double bonds at positions 8, 11 and 14.	1.99	1	0	fatty acid 20:3; long-chain fatty acid	fungal metabolite; human metabolite; nutraceutical
thromboxane b2 Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.	2.15	1	0	thromboxanes B	human metabolite; mouse metabolite
20-hydroxy-5,8,11,14-eicosatetraenoic acid 20-hydroxy-5,8,11,14-eicosatetraenoic acid: stimulator of renal sodium, potassium atpase; RN given is for the (all-Z) isomer. 20-HETE : A HETE that consists of arachidonic acid bearing a hydroxy substituent at position 20.	2.4	2	0	HETE; hydroxy monocarboxylic acid	human metabolite; mouse metabolite
11-hydroxy-9,12-octadecadienoic acid (9Z,12Z)-11-hydroxyoctadecadienoic acid : A HODE that is linoleic acid carrying a single hydroxy substituent at position 11.	2	1	0	HODE; secondary allylic alcohol
8-hydroxylinoleic acid 8-hydroxylinoleic acid: RN given refers to (9Z,12Z)-isomer; RN for cpd without isomeric designation not available 8/92	2	1	0
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid: RN given refers to (E,Z,Z,Z,Z,Z)-isomer; RN for cpd without isomeric designation not avail 3/90. (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosahexaenoic acid : A hydroxydocosahexaenoic acid that consists of 4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid bearing an additional 17-hydroxy substituent.	5.21	5	2	hydroxydocosahexaenoic acid; secondary allylic alcohol	human xenobiotic metabolite
19-hydroxy-5,8,11,14-eicosatetraenoic acid 19-hydroxy-5,8,11,14-eicosatetraenoic acid: potent stimulator of renal sodium, potassium atpase; RN given is for the (all-Z) isomer	3.1	5	0
14-hydroxydocosahexaenoate 14-hydroxydocosahexaenoic acid: RN given refers to cpd without isomeric designation	4.02	2	1
5s,12r,18r-trihydroxy-6z,8e,10e,14z,16e-eicosapentaenoic acid 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid: a bioactive oxygenated product of EPA, was identified in human plasma and prepared by total organic synthesis; structure in first source. resolvin E1 : A resolvin that is (6Z,8E,10E,14Z,16E)-icosa-6,8,10,14,16-pentaenoic acid which is substituted at positions 5, 12 and 18 by hydroxy groups (the 5S,12R,18R stereoisomer).	3.8	1	1	hydroxy polyunsaturated fatty acid; long-chain fatty acid; nonclassic icosanoid; resolvin; triol	anti-inflammatory agent; human xenobiotic metabolite
resolvin d2 resolvin D2: structure in first source; a potent endogenous regulator of excessive inflammatory responses that acts via multiple cellular targets to stimulate resolution and preserve immune vigilance. resolvin D2 : A member of the class of resolvins that is (4Z,8E,10Z,12E,14E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 7, 16 and 17 (the 7S,16R,17S-stereoisomer).	4.56	2	2	hydroxy polyunsaturated fatty acid; resolvin; secondary allylic alcohol; triol	anti-inflammatory agent; anti-obesity agent; estrogen receptor agonist; human xenobiotic metabolite; rat metabolite
pituitrin Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).	2.02	1	0
resolvin d5 resolvin D5: isolated from E coli; structure in first source. resolvin D5 : A member of the class of resolvins that is (4Z,8E,10Z,13Z,15E,19Z)-docosahexaenoic acid carrying two hydroxy substituents at positions 7 and 17 (the 7S,17S-stereoisomer).	3.8	1	1
cellulose DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.	1.97	1	0	glycoside
resolvin d1 resolvin D1: an anti-inflammatory lipid mediator; structure in first source. resolvin D1 : A resolvin that is docosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid which is substituted by hydroxy groups at the 7, 8, and 17 positions (the 7S,8R,17S-stereoisomer).	4.56	2	2	hydroxy polyunsaturated fatty acid; resolvin; triol	anti-inflammatory agent
resolvin D4 resolvin D4: a lipoxygenase-induced metabolite of docosahexaenoic acid (DHA) that is involved in host protection and bacterial clearance. resolvin D4 : A member of the class of resolvins that is (6E,8E,10Z,13Z,15E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 4, 5 and 17 (the 4S,5R,17S-stereoisomer).	3.8	1	1	hydroxy polyunsaturated fatty acid; resolvin; secondary allylic alcohol; triol	anti-inflammatory agent; human xenobiotic metabolite
resolvin d3 resolvin D3: structure in first source. resolvin D3 : A member of the class of resolvins that is (5Z,7E,9E,13Z,15E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 4, 11 and 17 (the 4S,11R,17S-stereoisomer).	3.8	1	1	hydroxy polyunsaturated fatty acid; resolvin; secondary allylic alcohol; triol	anti-inflammatory agent; human xenobiotic metabolite

Condition	Relationship Strength	Studies	Trials
Cardiometabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.	2.31	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.59	2	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	2.31	1	0
Pneumonia Infection of the lung often accompanied by inflammation.	2.31	1	0
Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.	2.31	1	0
Heart Disease, Ischemic [description not available]	3.8	1	1
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	3.8	1	1
Innate Inflammatory Response [description not available]	4.49	2	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	4.49	2	2
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	3.53	1	1
Diabetes Mellitus, Adult-Onset [description not available]	3.56	1	1
Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.	3.56	1	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	3.56	1	1
Chronic Kidney Diseases [description not available]	3.51	1	1
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	3.51	1	1
Polyarthritis [description not available]	2.13	1	0
Arthritis Acute or chronic inflammation of JOINTS.	2.13	1	0
Insulin Sensitivity [description not available]	2.13	1	0
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.13	1	0
Blood Pressure, High [description not available]	2.02	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	2.02	1	0

18-hydroxy-5,8,11,14-eicosatetraenoic acid

Description

Cross-References

Synonyms (5)

Research

Studies (15)

Study Types